Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy

Head and Neck

Volumn 28, Issue 7, 2006, Pages 620-625

  Watanabe, Akihito ^a   Taniguchi, Masanobu ^a   Yamashita, Tetsuro ^a   Ueda, Michihiro ^a   Abe, Tatsuya ^a   Kusumi, Takaya ^a   Hosokawa, Masao ^a   Sasaki, Shigeyuki ^b  

^a KEIYUKAI SAPPORO HOSPITAL   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Carboplatin; Outpatient chemotherapy; Phase I II study; Recurrent head and neck cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; FATIGUE; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HOSPITALIZATION; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LEUKOPENIA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUTH CANCER; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; OUTPATIENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AMBULATORY CARE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DRUG COMBINATIONS; HEAD AND NECK NEOPLASMS; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; TEGAFUR;

EID: 33745777162     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20379     Document Type: Article

References (21)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Dimery IW, Hong WK. Overview of combined modality for head and neck cancer. J Natl Cancer Inst 1993;85:95-110.
3. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-2606.
4. Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987;78:748-755.
5. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009.
6. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advance head and neck cancer [in Japanese with English abstract]. Jpn J Cancer Chemother 2001;28:1381-1390.
7. Canetta R, Bragman K, Smaldone L, Rozencweig M. Carboplatin: current status and future prospects. Cancer Treat Rev 1988;15:17-32.
8. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete objections. J Am Stat Ass 1958;53:457-481.
11. Kish J, Drelichman A, Jacobs J, et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982;66:471-474.
12. Schuler DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-1211.
13. Vokes EE, Mick R, Lester EP, Panje WR, Weichselbaum RR. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol 1991;9:1376-1384.
14. Choksi AJ, Hong WK, Dimery IW, James P, Guillamondegui OM, Byers RM. Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma. Cancer 1988;61:909-912.
15. O'Brien M, Schfield JB, Loretzos A, et al. The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck. Oral Oncol, Eur J Cancer 1994;30:265-267.
16. Clavel M, Vermoken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521-526.
17. Paccagnella A, Pappagallo GL, Segati R, et al. Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreatment and untreated patients with advanced epidermoid cancer of the head and neck. Am J Clin Oncol 1990;13:194-198.
18. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergists antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993;32:167-172.
19. Koizumi W, Tanabe S, Saigenji K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212.
20. Ichinose Y, Takanashi N, Yano T, et al. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non-small cell lung cancer. Cancer 1995;75:2677-2680.
21. Shiozaki A, Yamagishi H, Itoi H, et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep 2005;13:667-672.